Skip to main content
Erschienen in: Medical Microbiology and Immunology 3/2012

01.08.2012 | Original Investigation

Herpes simplex virus type 1 induces simultaneous activation of Toll-like receptors 2 and 4 and expression of the endogenous ligand serum amyloid A in astrocytes

verfasst von: Melina Villalba, Melissa Hott, Carolina Martin, Blanca Aguila, Sharin Valdivia, Claudia Quezada, Ángara Zambrano, Margarita I. Concha, Carola Otth

Erschienen in: Medical Microbiology and Immunology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Herpes simplex virus type 1 (HSV-1) is the most common pathogenic cause of sporadic acute encephalitis and it produces latent persistent infection lifelong in infected individuals. Brain inflammation is associated with activation of glial cells, which can detect pathogen-associated molecular patterns (PAMPs) through a variety of pattern-recognition receptors (PRR), including Toll-like receptors (TLRs). In this study, we evaluated the expression and activation of TLR2, TLR3, and TLR4 in HSV-1-infected astrocyte and neuronal primary cultures. Our results showed a clear induction in TLR2 and TLR4 expression in astrocytes as early as 1 h after HSV-1 infection, whereas no significant change was observed in neurons. In addition, infected astrocytes showed increased levels of interferon regulatory factors IRF3 and IRF7, interferon β (INFβ), interleukin 6 (IL6), and serum amyloid A (SAA3) transcripts, as well as phospho-IRF3 protein. These effects seemed to be dependent on viral replication since previous treatment of the cells with acyclovir resulted in low levels of TLRs expression and activation even after 4 h post-infection. These results suggest that reactivation of HSV-1 at the central nervous system (CNS) would likely induce and activate TLR2 and TLR4 receptors directly through interaction of astrocytes with the pathogen and also indirectly by endogenous ligands produced locally, such as serum amyloid protein, potentiating the neuroinflammatory response.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wozniak MA, Shipley SJ, Combrinck M, Wilcock GK, Itzhaki RF (2005) Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer’s disease patients. J Med Virol 75(2):300–306PubMedCrossRef Wozniak MA, Shipley SJ, Combrinck M, Wilcock GK, Itzhaki RF (2005) Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer’s disease patients. J Med Virol 75(2):300–306PubMedCrossRef
2.
Zurück zum Zitat Letenneur L, Pérès K, Fleury H, Garrigue I, Barberger-Gateau P, Helmer C, Orgogozo JM, Gauthier S, Dartigues JF (2008) Seropositivity to herpes simplex virus antibodies and risk of Alzheimer’s disease: a population-based cohort study. PLoS ONE 3(11):e3637. doi:10.1371/journal.pone.0003637 PubMedCrossRef Letenneur L, Pérès K, Fleury H, Garrigue I, Barberger-Gateau P, Helmer C, Orgogozo JM, Gauthier S, Dartigues JF (2008) Seropositivity to herpes simplex virus antibodies and risk of Alzheimer’s disease: a population-based cohort study. PLoS ONE 3(11):e3637. doi:10.​1371/​journal.​pone.​0003637 PubMedCrossRef
3.
Zurück zum Zitat Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA (1997) Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. Lancet 349(9047):241–244PubMedCrossRef Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA (1997) Herpes simplex virus type 1 in brain and risk of Alzheimer’s disease. Lancet 349(9047):241–244PubMedCrossRef
4.
Zurück zum Zitat Itzhaki RF, Wozniak MA (2006) Herpes simplex virus type 1, apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer’s disease and other disorders. Prog Lipid Res 45(1):73–90PubMedCrossRef Itzhaki RF, Wozniak MA (2006) Herpes simplex virus type 1, apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer’s disease and other disorders. Prog Lipid Res 45(1):73–90PubMedCrossRef
5.
Zurück zum Zitat Itzhaki RF, Wozniak MA, Appelt DM, Balin BJ (2004) Infiltration of the brain by pathogens causes Alzheimer’s disease. Neurobiol Aging 25(5):619–627PubMedCrossRef Itzhaki RF, Wozniak MA, Appelt DM, Balin BJ (2004) Infiltration of the brain by pathogens causes Alzheimer’s disease. Neurobiol Aging 25(5):619–627PubMedCrossRef
6.
Zurück zum Zitat Dobson CB, Wozniak MA, Itzhaki RF (2003) Do infectious agents play a role in dementia? Trends Microbiol 11(7):312–317PubMedCrossRef Dobson CB, Wozniak MA, Itzhaki RF (2003) Do infectious agents play a role in dementia? Trends Microbiol 11(7):312–317PubMedCrossRef
7.
Zurück zum Zitat Zambrano A, Solis L, Salvadores N, Cortés M, Lerchundi R, Otth C (2008) Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with herpes simplex virus type 1. J Alzheimer Dis 14(3):1–11 Zambrano A, Solis L, Salvadores N, Cortés M, Lerchundi R, Otth C (2008) Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with herpes simplex virus type 1. J Alzheimer Dis 14(3):1–11
8.
Zurück zum Zitat Otth C, Zambrano A, Concha M (2009) The possible link between herpes simplex virus type 1 infection and neurodegeneration. In: Maccioni RB, Perry G (eds) Current hypotheses and research Milestones in Alzheimer’s disease. Springer, New York, pp 181–188. ISBN 978-0-387-87994-9 Otth C, Zambrano A, Concha M (2009) The possible link between herpes simplex virus type 1 infection and neurodegeneration. In: Maccioni RB, Perry G (eds) Current hypotheses and research Milestones in Alzheimer’s disease. Springer, New York, pp 181–188. ISBN 978-0-387-87994-9
9.
Zurück zum Zitat Lerchundi R, Neira R, Valdivia S, Vio K, Concha MI, Zambrano A, Otth C (2011) Tau cleavage at D421 by caspase-3 is induced in neurons and astrocytes infected with Herpes Simplex Virus type 1. J Alzheimer Dis 23(3):513–520 Lerchundi R, Neira R, Valdivia S, Vio K, Concha MI, Zambrano A, Otth C (2011) Tau cleavage at D421 by caspase-3 is induced in neurons and astrocytes infected with Herpes Simplex Virus type 1. J Alzheimer Dis 23(3):513–520
10.
Zurück zum Zitat Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124(4):783–801PubMedCrossRef Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124(4):783–801PubMedCrossRef
11.
Zurück zum Zitat Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K (2007) Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem 20(6):947–956PubMedCrossRef Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, Bode B, Manietta N, Walter J, Schulz-Schuffer W, Fassbender K (2007) Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol Biochem 20(6):947–956PubMedCrossRef
12.
Zurück zum Zitat He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD (2009) Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 113(2):429–437PubMedCrossRef He RL, Zhou J, Hanson CZ, Chen J, Cheng N, Ye RD (2009) Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 113(2):429–437PubMedCrossRef
13.
Zurück zum Zitat Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A (2008) Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol 83(5):1174–1180PubMedCrossRef Sandri S, Rodriguez D, Gomes E, Monteiro HP, Russo M, Campa A (2008) Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol 83(5):1174–1180PubMedCrossRef
14.
Zurück zum Zitat Cheng N, He R, Tian J, Ye PP, Ye RD (2008) Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 181(1):22–26PubMed Cheng N, He R, Tian J, Ye PP, Ye RD (2008) Cutting edge: TLR2 is a functional receptor for acute-phase serum amyloid A. J Immunol 181(1):22–26PubMed
15.
Zurück zum Zitat Liang JS, Sloane JA, Wells JM, Abraham CR, Fine RE, Sipe JD (1997) Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer’s disease brain. Neurosci Lett 225(2):73–76PubMedCrossRef Liang JS, Sloane JA, Wells JM, Abraham CR, Fine RE, Sipe JD (1997) Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer’s disease brain. Neurosci Lett 225(2):73–76PubMedCrossRef
16.
Zurück zum Zitat Kindy MS, Yu J, Guo JT, Zhu H (1999) Apolipoprotein serum amyloid A in Alzheimer’s disease. J Alzheimer Dis 1(3):155–167 Kindy MS, Yu J, Guo JT, Zhu H (1999) Apolipoprotein serum amyloid A in Alzheimer’s disease. J Alzheimer Dis 1(3):155–167
17.
Zurück zum Zitat Chung TF, Sipe JD, McKee A, Fine RE, Schreiber BM, Liang JS, Johnson RJ (2000) Serum amyloid A in Alzheimer’s disease brain is predominantly localized to myelin sheaths and axonal membrane. Amyloid 7(2):105–110PubMedCrossRef Chung TF, Sipe JD, McKee A, Fine RE, Schreiber BM, Liang JS, Johnson RJ (2000) Serum amyloid A in Alzheimer’s disease brain is predominantly localized to myelin sheaths and axonal membrane. Amyloid 7(2):105–110PubMedCrossRef
19.
Zurück zum Zitat Castro MA, Pozo M, Cortés C, García M, Concha II, Nualart F (2007) Intracellular ascorbic acid inhibits transport of glucose by neurons, but not by astrocytes. J Neurochem 102(3):773–782PubMedCrossRef Castro MA, Pozo M, Cortés C, García M, Concha II, Nualart F (2007) Intracellular ascorbic acid inhibits transport of glucose by neurons, but not by astrocytes. J Neurochem 102(3):773–782PubMedCrossRef
20.
Zurück zum Zitat Otth C, Torres M, Ramirez A, Fernandez JC, Castro M, Rauch MC, Brito M, Yanez AJ, Rodriguez-Gil JE, Slebe JC, Concha II (2007) Novel identification of peripheral dopaminergic D2 receptor in male germ cells. J Cell Biochem 100(1):141–150PubMedCrossRef Otth C, Torres M, Ramirez A, Fernandez JC, Castro M, Rauch MC, Brito M, Yanez AJ, Rodriguez-Gil JE, Slebe JC, Concha II (2007) Novel identification of peripheral dopaminergic D2 receptor in male germ cells. J Cell Biochem 100(1):141–150PubMedCrossRef
21.
Zurück zum Zitat Du F, Qian ZM, Zhu L, Wu XM, Qian C, Chan R, Ke Y (2010) Purity, cell viability, expression of GFAP and bystin in astrocytes cultured by different procedures. J Cell Biochem 109(1):30–37PubMed Du F, Qian ZM, Zhu L, Wu XM, Qian C, Chan R, Ke Y (2010) Purity, cell viability, expression of GFAP and bystin in astrocytes cultured by different procedures. J Cell Biochem 109(1):30–37PubMed
22.
Zurück zum Zitat Hua F, Ma J, Ha T, Kelley JL, Kao RL, Schweitzer JB, Kalbfleisch JH, Williams DL, Li C (2009) Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice. Brain Res 1262:100–108PubMedCrossRef Hua F, Ma J, Ha T, Kelley JL, Kao RL, Schweitzer JB, Kalbfleisch JH, Williams DL, Li C (2009) Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice. Brain Res 1262:100–108PubMedCrossRef
23.
Zurück zum Zitat Hyakkoku K, Hamanaka J, Tsuruma K, Shimazawa M, Tanaka H, Uematsu S, Akira S, Inagaki N, Nagai H, Hara H (2010) Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 171(1):258–267PubMedCrossRef Hyakkoku K, Hamanaka J, Tsuruma K, Shimazawa M, Tanaka H, Uematsu S, Akira S, Inagaki N, Nagai H, Hara H (2010) Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 171(1):258–267PubMedCrossRef
24.
Zurück zum Zitat Aravalli RN, Hu S, Rowen TN, Palmquist JM, Lokensgard JR (2005) Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol 175(7):4189–4193PubMed Aravalli RN, Hu S, Rowen TN, Palmquist JM, Lokensgard JR (2005) Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol 175(7):4189–4193PubMed
25.
Zurück zum Zitat Wang JP, Bowen GN, Zhou S, Cerny A, Zacharia A, Knipe DM, Finberg RW, Kurt-Jones EA (2012) Role of specific innate immune responses in herpes simplex virus infection of the central nervous system. J Virol 86(4):2273–2281PubMedCrossRef Wang JP, Bowen GN, Zhou S, Cerny A, Zacharia A, Knipe DM, Finberg RW, Kurt-Jones EA (2012) Role of specific innate immune responses in herpes simplex virus infection of the central nervous system. J Virol 86(4):2273–2281PubMedCrossRef
27.
Zurück zum Zitat Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV (2009) Toll-like receptors in neurodegeneration. Brain Res Rev 59(2):278–292PubMedCrossRef Okun E, Griffioen KJ, Lathia JD, Tang SC, Mattson MP, Arumugam TV (2009) Toll-like receptors in neurodegeneration. Brain Res Rev 59(2):278–292PubMedCrossRef
28.
Zurück zum Zitat Tsitoura E, Thomas J, Cuchet D, Thoinet K, Mavromara P, Epstein AL (2009) Infection with herpes simplex type 1-based amplicon vectors results in an IRF3/7-dependent, TLR-independent activation of the innate antiviral response in primary human fibroblasts. J Gen Virol 90(Pt 9):2209–2220PubMedCrossRef Tsitoura E, Thomas J, Cuchet D, Thoinet K, Mavromara P, Epstein AL (2009) Infection with herpes simplex type 1-based amplicon vectors results in an IRF3/7-dependent, TLR-independent activation of the innate antiviral response in primary human fibroblasts. J Gen Virol 90(Pt 9):2209–2220PubMedCrossRef
29.
Zurück zum Zitat Collins SE, Noyce RS, Mossman KL (2004) Innate cellular response to virus particle entry requires IRF3 but not virus replication. J Virol 78(4):1706–1717PubMedCrossRef Collins SE, Noyce RS, Mossman KL (2004) Innate cellular response to virus particle entry requires IRF3 but not virus replication. J Virol 78(4):1706–1717PubMedCrossRef
30.
Zurück zum Zitat Noyce RS, Collins SE, Mossman KL (2009) Differential modification of interferon regulatory factor 3 following virus particle entry. J Virol 83(9):4013–4422PubMedCrossRef Noyce RS, Collins SE, Mossman KL (2009) Differential modification of interferon regulatory factor 3 following virus particle entry. J Virol 83(9):4013–4422PubMedCrossRef
31.
Zurück zum Zitat Paladino P, Cummings DT, Noyce RS, Mossman KL (2006) The IFN-independent response to virus particle entry provides a first line of antiviral defense that is independent of TLRs and retinoic acid-inducible gene I. J Immunol 177(11):8008–8016PubMed Paladino P, Cummings DT, Noyce RS, Mossman KL (2006) The IFN-independent response to virus particle entry provides a first line of antiviral defense that is independent of TLRs and retinoic acid-inducible gene I. J Immunol 177(11):8008–8016PubMed
32.
Zurück zum Zitat Rasmussen SB, Sørensen LN, Malmgaard L, Ank N, Baines JD, Chen ZJ, Paludan SR (2007) Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J Virol 81(24):13315–13324PubMedCrossRef Rasmussen SB, Sørensen LN, Malmgaard L, Ank N, Baines JD, Chen ZJ, Paludan SR (2007) Type I interferon production during herpes simplex virus infection is controlled by cell-type-specific viral recognition through Toll-like receptor 9, the mitochondrial antiviral signaling protein pathway, and novel recognition systems. J Virol 81(24):13315–13324PubMedCrossRef
33.
Zurück zum Zitat Niemi K, Teirilä L, Lappalainen J, Rajamäki K, Baumann MH, Öörni K, Wolff H, Kovanen PT, Matikainen S, Eklund KK (2011) Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and cathepsin B-sensitive pathway. J Immunol 186(11):61119–66128CrossRef Niemi K, Teirilä L, Lappalainen J, Rajamäki K, Baumann MH, Öörni K, Wolff H, Kovanen PT, Matikainen S, Eklund KK (2011) Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and cathepsin B-sensitive pathway. J Immunol 186(11):61119–66128CrossRef
34.
Zurück zum Zitat Chiba T, Han CY, Vaisar T, Shimokado K, Kargi A, Chen MH, Wang S, McDonald TO, O’Brien KD, Heinecke JW, Chait A (2009) Serum amyloid A3 does not contribute to circulating SAA levels. J Lipid Res 50(7):1353–1362PubMedCrossRef Chiba T, Han CY, Vaisar T, Shimokado K, Kargi A, Chen MH, Wang S, McDonald TO, O’Brien KD, Heinecke JW, Chait A (2009) Serum amyloid A3 does not contribute to circulating SAA levels. J Lipid Res 50(7):1353–1362PubMedCrossRef
35.
Zurück zum Zitat Reigstad CS, Bäckhed F (2010) Microbial regulation of SAA3 expression in mouse colon and adipose tissue. Gut Microbes 1(1):55–57PubMedCrossRef Reigstad CS, Bäckhed F (2010) Microbial regulation of SAA3 expression in mouse colon and adipose tissue. Gut Microbes 1(1):55–57PubMedCrossRef
36.
Zurück zum Zitat Conde J, Gomez R, Bianco G, Scotese M, Lear P, Dieguez C, Gomez-Reino J, Lago F, Gualillo O (2011) Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. Ann Rheum Dis 70(3):551–559 Conde J, Gomez R, Bianco G, Scotese M, Lear P, Dieguez C, Gomez-Reino J, Lago F, Gualillo O (2011) Expanding the adipokine network in cartilage: identification and regulation of novel factors in human and murine chondrocytes. Ann Rheum Dis 70(3):551–559
37.
Zurück zum Zitat Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE, Fitzgerald KA, Flavell RA, Eisenbarth SC, Poynter ME (2011) Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol 187(1):64–73PubMedCrossRef Ather JL, Ckless K, Martin R, Foley KL, Suratt BT, Boyson JE, Fitzgerald KA, Flavell RA, Eisenbarth SC, Poynter ME (2011) Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J Immunol 187(1):64–73PubMedCrossRef
38.
Zurück zum Zitat Ridder DA, Bulashevska S, Chaitanya GV, Babu PP, Brors B, Eils R, Schneider A, Schwaninger M (2009) Discovery of transcriptional programs in cerebral ischemia by in silico promoter analysis. Brain Res 1272:3–13PubMedCrossRef Ridder DA, Bulashevska S, Chaitanya GV, Babu PP, Brors B, Eils R, Schneider A, Schwaninger M (2009) Discovery of transcriptional programs in cerebral ischemia by in silico promoter analysis. Brain Res 1272:3–13PubMedCrossRef
39.
Zurück zum Zitat Ejarque-Ortíz A, Medina MG, Tusell JM, Pérez-González AP, Serratosa J, Saura J (2007) Upregulation of CCAAT/enhancer binding protein β in activated astrocytes and microglia. Glia 55(2):178–188PubMedCrossRef Ejarque-Ortíz A, Medina MG, Tusell JM, Pérez-González AP, Serratosa J, Saura J (2007) Upregulation of CCAAT/enhancer binding protein β in activated astrocytes and microglia. Glia 55(2):178–188PubMedCrossRef
Metadaten
Titel
Herpes simplex virus type 1 induces simultaneous activation of Toll-like receptors 2 and 4 and expression of the endogenous ligand serum amyloid A in astrocytes
verfasst von
Melina Villalba
Melissa Hott
Carolina Martin
Blanca Aguila
Sharin Valdivia
Claudia Quezada
Ángara Zambrano
Margarita I. Concha
Carola Otth
Publikationsdatum
01.08.2012
Verlag
Springer-Verlag
Erschienen in
Medical Microbiology and Immunology / Ausgabe 3/2012
Print ISSN: 0300-8584
Elektronische ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-012-0247-0

Weitere Artikel der Ausgabe 3/2012

Medical Microbiology and Immunology 3/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.